Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

Keyphrases

• Epidermal Growth Factor Receptor 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 100%
• Acquired Resistance 100%
• Molecular Mechanism 50%
• Tyrosine Kinase Inhibitor 50%
• Erlotinib 50%
• Gefitinib 50%
• Angiogenesis 25%
• Non-small Cell Lung Cancer Patients 25%
• Metastasis 25%
• Overexpression 25%
• Apoptotic Pathway 25%
• Drug Resistance 25%
• NewHope 25%
• Anti-apoptotic 25%
• T790M 25%
• Epithelial-mesenchymal Transition 25%
• Hepatocyte Growth Factor 25%
• Invasion Resistance 25%
• MET Amplification 25%
• Epithelial Cancer 25%
• Proliferation Resistance 25%
• Secondary mutation 25%
• Tyrosine Kinase Inhibition 25%
• Receptor Tyrosine Kinase 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Epidermal Growth Factor Receptor 80%
• Erlotinib 40%
• Protein Tyrosine Kinase Inhibitor 40%
• Gefitinib 40%
• Malignant Neoplasm 20%
• Drug Resistance 20%
• Antiapoptotic 20%
• Protein Tyrosine Kinase 20%
• Scatter Factor 20%